Collaboration with the pharmaceutical industry is essential in order to achieve the translation of preclinical research findings into clinical trials and treatments for patients. Dr Lochmüller is a key opinion leader in neuromuscular disease clinical research who is sought after for pharmaceutical industry advisory boards and as a principal investigator for clinical trials.
Impaired neuromuscular transmission, GNE myopathy and various muscular dystrophies including myotonic dystrophy and Duchenne muscular dystrophy are the main focus of our current industry collaborations. Dr Lochmüller has conducted numerous commercially sponsored and academic-led pre-clinical and clinical trials, and recent partners include GSK, Roche, Neurotune, Amplo Biotechnology, Argenx, Ultragenyx, and AMO Pharma.
Importantly, as well as working with pharma in preclinical and clinical research studies, we work with patients and patient groups to establish their needs and priorities for such research. Patient preferences are studied and taken into consideration. While working in Europe, Hanns was responsible for the neuromuscular arm of the PREFER IMI project, an industry-academic collaboration established in 2016.